[2] Hoerr graduated from the Johannes-Kepler-Realschule in Wendlingen am Neckar in 1985 [3] and then attended an agricultural high school in Nürtingen, where he obtained his Abitur in 1988.

In 2000, Hoerr published his doctoral thesis entitled "RNA vaccine for the induction of specific cytotoxic T-lymphocytes (CTL) and antibodies."

Rather, stabilized RNA stimulates the immune system to produce antibodies and activate T cells that destroy pathogens.

[9][10] Bill Gates, whose foundation invested in CureVac, rated Hoerr's pioneering work as groundbreaking in an interview with German newspaper Handelsblatt: "The first mRNA vaccines,developed by Pfizer-Biontech and Moderna in 2020, are the product of a multitude of ideas and discoveries by German scientist Ingmar Hoerr, who spent twenty years experimenting with messenger RNA.

Der Spiegel ranked him among the pioneers of m-RNA vaccines,[12] as did Die Zeit[13] or Süddeutsche Zeitung[14] and conducted interviews.

[19] In 2000, Hoerr, together with colleagues from the lab groups of Günther Jung and Hans-Georg Rammensee, founded the biopharmaceutical company CureVac.